(Q52901455)

9 May 2018

title

Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. (English)

1 reference

9 May 2018

1 reference

Laura W Goff

1

1 reference

9 May 2018

Al B Benson

2

1 reference

9 May 2018

Patricia M LoRusso

3

1 reference

9 May 2018

Antoinette R Tan

4

1 reference

9 May 2018

Jordan D Berlin

5

1 reference

9 May 2018

Louis J Denis

6

1 reference

9 May 2018

Rebecca J Benner

7

1 reference

9 May 2018

Donghua Yin

8

1 reference

9 May 2018

Mace L Rothenberg

9

1 reference

9 May 2018

publication date

21 September 2010

1 reference

9 May 2018

Investigational New Drugs

published in

1 reference

9 May 2018

volume

30

1 reference

9 May 2018

issue

1

1 reference

9 May 2018

page(s)

290-298

1 reference

9 May 2018

https://scigraph.springernature.com/pub.10.1007/s10637-010-9528-x

exact match

0 references

cites work

The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Topoisomerase I inhibitors: review and update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9528-X

Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20857171

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20857171

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20857171

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-010-9528-X

1 reference

9 May 2018

1 reference

9 May 2018